

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3511276/publications.pdf Version: 2024-02-01



YAO XIE

#	Article	lF	CITATIONS
1	Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virologica Sinica, 2022, 37, 390-397.	1.2	10
2	Hepatitis B coreâ€related antigen serum levels are associated with significant liver fibrosis in treatmentâ€naive chronic HBV infection patients. Journal of Viral Hepatitis, 2022, 29, 438-446.	1.0	1
3	Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients. Frontiers in Immunology, 2022, 13, .	2.2	10
4	Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection. Frontiers in Immunology, 2022, 13, .	2.2	7
5	Cytokine Profiles and Virological Marker Monitoring during 48 Weeks Peginterferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Biomedical and Environmental Sciences, 2022, 35, 312-321.	0.2	1
6	Pathway of Cell Death and Its Role in Virus Infection. Viral Immunology, 2022, 35, 444-456.	0.6	4
7	Developmental Consequences of Prenatal Telbivudine Exposure during the Third Trimester. Clinical Gastroenterology and Hepatology, 2021, 19, 1061-1063.	2.4	2
8	Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virologica Sinica, 2021, 36, 311-320.	1.2	17
9	Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up. Virulence, 2021, 12, 1527-1537.	1.8	2
10	The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. BioMed Research International, 2021, 2021, 1-14.	0.9	11
11	Secondary hemophagocytic lymphohistiocytosis characterized by liver injury. Medicina ClÃnica, 2021, 157, 548-549.	0.3	0
12	Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver International, 2021, 41, 1498-1508.	1.9	24
13	Transforming growth factor $\hat{l}^2$ as a possible independent factor in chronic hepatitis B. Archives of Virology, 2021, 166, 1853-1858.	0.9	4
14	Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report. Viral Immunology, 2021, , .	0.6	5
15	Application of Lab-on-Chip for Detection of Microbial Nucleic Acid in Food and Environment. Frontiers in Microbiology, 2021, 12, 765375.	1.5	5
16	Advances in Metagenomics and Its Application in Environmental Microorganisms. Frontiers in Microbiology, 2021, 12, 766364.	1.5	54
17	Changes in the Cytokine Profiles of Patients with Chronic Hepatitis B during Antiviral Therapy. Biomedical and Environmental Sciences, 2021, 34, 443-453.	0.2	9
18	Association of cytokines with hepatitis B virus and its antigen. Journal of Medical Virology, 2020, 92, 3426-3435.	2.5	12

ΥΑΟ ΧΙΕ

#	Article	IF	CITATIONS
19	The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients. BMC Infectious Diseases, 2020, 20, 590.	1.3	4
20	Field applicable detection of hepatitis B virus using internal controlled duplex recombinaseâ€ <b>e</b> ided amplification assay and lateral flow dipstick assay. Journal of Medical Virology, 2020, 92, 3344-3353.	2.5	17
21	Comparison of third-generation sequencing approaches to identify viral pathogens under public health emergency conditions. Virus Genes, 2020, 56, 288-297.	0.7	17
22	Predictors of sustained functional cure in hepatitis B envelope antigenâ€negative patients achieving hepatitis B surface antigen seroclearance with interferonâ€alpha–based therapy. Journal of Viral Hepatitis, 2019, 26, 32-41.	1.0	27
23	Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigenâ€negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. Journal of Viral Hepatitis, 2019, 26, 42-49.	1.0	17
24	Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clinical and Experimental Medicine, 2019, 19, 309-320.	1.9	12
25	Applicability of duplex real time and lateral flow strip reverse-transcription recombinase aided amplification assays for the detection of Enterovirus 71 and Coxsackievirus A16. Virology Journal, 2019, 16, 166.	1.4	14
26	A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a. Journal of Clinical and Translational Hepatology, 2019, 7, 1-9.	0.7	4
27	Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. Journal of Clinical and Translational Hepatology, 2019, 7, 1-5.	0.7	9
28	The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. American Journal of Gastroenterology, 2018, 113, 686-693.	0.2	32
29	Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B. Chinese Medical Journal, 2018, 131, 1813-1818.	0.9	14
30	Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection. Chinese Medical Journal, 2018, 131, 43-49.	0.9	10
31	Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy. Journal of Interferon and Cytokine Research, 2018, 38, 197-205.	0.5	14
32	HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. Journal of Clinical and Translational Hepatology, 2018, 6, 1-10.	0.7	82
33	Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 470-479.	0.6	9
34	Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Chinese Medical Journal, 2017, 130, 559-565.	0.9	21
35	Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-naÃ <sup>-</sup> ve Patients with Chronic Hepatitis B Virus Infection. Chinese Medical Journal, 2017, 130, 2697-2702.	0.9	11
36	Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B. Chinese Medical Journal, 2017, 130, 1810-1815.	0.9	11

ΥΑΟ ΧΙΕ

#	Article	IF	CITATIONS
37	The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment. Biomedical and Environmental Sciences, 2017, 30, 177-184.	0.2	15
38	Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World Journal of Hepatology, 2016, 8, 637.	0.8	22
39	Case Report: Both Mother and Child With Chronic HBV Infection Were Clinically Cured After PEG-IFN Treatment. , 0, , .		0